title: Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient.
abstract: Lung transplantation is an accepted therapy for children with end-stage lung disease. One-year lung transplant survival rates of 86% have been reported by the United Network for Organ Sharing. Allograft rejection is a common cause of death following transplantation. Extracorporeal photopheresis is a novel therapy used to treat solid-organ rejection; this therapy involves separating the leukocyte-rich fraction from whole blood, treating with psoralen and ultraviolet light A exposure. The objective of therapy is to reverse progressive and persistent rejection. Working collaboratively with an institution that offers extracorporeal photopheresis may provide an alternative or additional therapy in the management of ongoing rejection following solid-organ transplantation.
authors.affiliation: University of Pittsburgh School of Nursing, Pittsburgh, Pa, USA.
authors.forename: Barbara V
authors.initials: BV
authors.lastname: Wise
authors.forename: Karen E
authors.initials: KE
authors.lastname: King
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Mogayzel
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D003550:Cystic Fibrosis / Q000601:surgery*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016040:Lung Transplantation; D017893:Photopheresis
chemical_list: D007166:Immunosuppressive Agents